These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32467427)

  • 1. Nitrosamine Impurities in Angiotensin Receptor Blockers.
    Shephard EA; Nawarskas JJ
    Cardiol Rev; 2020; 28(5):262-265. PubMed ID: 32467427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
    Bharate SS
    J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Status of Angiotensin Receptor Blocker Recalls.
    Gunasekaran PM; Chertow GM; Bhalla V; Byrd JB
    Hypertension; 2019 Dec; 74(6):1275-1278. PubMed ID: 31630573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure to Valsartan Products Containing Nitrosamine Impurities in the United States, Canada, and Denmark.
    Eworuke E; Shinde MU; Hou L; Paterson JM; Jensen PB; Maro JC; Rai A; Pottegård A; Scarnecchia D; Liang Y; Johnson D; Platt RW; Lee H; Bradley MC
    Pharmacoepidemiol Drug Saf; 2024 Sep; 33(9):e5849. PubMed ID: 39289955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NITROSOGENESIS OF SKIN (HUMAN) CANCER- THE HIDDEN TRUTH OF A NEVERENDING STORY: NITROSAMINE CONTAMINATION IN OLMESARTAN, VALSARTAN AND HCT AS MAIN RISK FACTOR FOR THE DEVELOPMENT OF KERATINOCYTE CANCER.
    Tchernev G; Kordeva S
    Georgian Med News; 2023 Apr; (337):63-67. PubMed ID: 37354675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MULTIPLE BCCS AND DYSPLASTIC NEVI AFTER ACE INHIBITORS (ENALAPRIL/PERINDOPRIL): THE ROLE OF NITROSAMINE CONTAMINATION/AVAILABILITY AS SUBSTANTIAL SKIN CANCER TRIGGERING FACTOR.
    Tchernev G; Kordeva S
    Georgian Med News; 2023 Feb; (335):90-94. PubMed ID: 37042596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare.
    Gillette M; Taylor A; Butulija D; Kadiyala H; Jneid H
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):579-584. PubMed ID: 32318933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control.
    Tuesuwan B; Vongsutilers V
    J Pharm Sci; 2021 Sep; 110(9):3118-3128. PubMed ID: 33989680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertension Hot Potato - Anatomy of the Angiotensin-Receptor Blocker Recalls.
    Byrd JB; Chertow GM; Bhalla V
    N Engl J Med; 2019 Apr; 380(17):1589-1591. PubMed ID: 30865819
    [No Abstract]   [Full Text] [Related]  

  • 10. Neoplasm Reports in Food and Drug Administration Adverse Event Reporting System Following Angiotensin Receptor Blocker Recalls.
    Cohen Sedgh R; Moon J; Jackevicius CA
    Circ Cardiovasc Qual Outcomes; 2021 Aug; 14(8):e007476. PubMed ID: 34380327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
    Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
    Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
    Charoo NA; Ali AA; Buha SK; Rahman Z
    AAPS PharmSciTech; 2019 Apr; 20(5):166. PubMed ID: 30989447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is this the end for ranitidine? NDMA presence continues to confound.
    Wagner JA; Dinh JC; Lightdale JR; Gold BD; Colombo JM
    Clin Transl Sci; 2021 Jul; 14(4):1197-1200. PubMed ID: 33934515
    [No Abstract]   [Full Text] [Related]  

  • 14. Current Threat of Nitrosamines in Pharmaceuticals and Scientific Strategies for Risk Mitigation.
    Tuesuwan B; Vongsutilers V
    J Pharm Sci; 2023 May; 112(5):1192-1209. PubMed ID: 36739905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitrosamine Impurities in Herbal Formulations: A Review of Risks and Mitigation Strategies.
    Shekhar NR; Nagappan K; Singh MT; Dhanabal SP
    Drug Res (Stuttg); 2023 Oct; 73(8):431-440. PubMed ID: 37487523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities.
    Scherf-Clavel O; Kinzig M; Besa A; Schreiber A; Bidmon C; Abdel-Tawab M; Wohlfart J; Sörgel F; Holzgrabe U
    J Pharm Biomed Anal; 2019 Aug; 172():278-284. PubMed ID: 31078064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
    Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
    J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
    Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
    Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin Receptor Blockers and the Risk of Cancer: Insights from Clinical Trials and Recent Drug Recalls.
    Berrido AM; Byrd JB
    Curr Hypertens Rep; 2020 Feb; 22(3):20. PubMed ID: 32114653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding and Preventing (
    White CM
    Ann Pharmacother; 2020 Jun; 54(6):611-614. PubMed ID: 31771343
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.